loading

Halozyme Therapeutics Inc (HALO) 最新ニュース

pulisher
Apr 25, 2025

H.C. Wainwright maintains Buy on Halozyme stock, $72 target By Investing.com - Investing.com South Africa

Apr 25, 2025
pulisher
Apr 25, 2025

Halozyme sues Merck; FDA blames cuts for Vanda delay - BioPharma Dive

Apr 25, 2025
pulisher
Apr 25, 2025

H.C. Wainwright maintains Buy on Halozyme stock, $72 target - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga

Apr 25, 2025
pulisher
Apr 25, 2025

Halozyme files lawsuit against Merck over SC Keytruda - The Pharma Letter

Apr 25, 2025
pulisher
Apr 24, 2025

Halozyme sues Merck over alleged patent infringement By Investing.com - Investing.com South Africa

Apr 24, 2025
pulisher
Apr 24, 2025

Halozyme sues Merck, alleging injectable Keytruda will infringe its patents - Endpoints News

Apr 24, 2025
pulisher
Apr 24, 2025

Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief - MSN

Apr 24, 2025
pulisher
Apr 24, 2025

Merck Faces Lawsuit to Block Launch of Easier-to-Use Keytruda - Bloomberg

Apr 24, 2025
pulisher
Apr 24, 2025

Halozyme Therapeutics (HALO) Files Lawsuit Against Merck Over Patent Infringement - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Merck stock flat despite Halozyme patent suit (MRK:NYSE) - Seeking Alpha

Apr 24, 2025
pulisher
Apr 24, 2025

Halozyme Files Patent Infringement Lawsuit Against Merck - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

Halozyme sues Merck over alleged patent infringement - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Halozyme (HALO) Sues Merck Over Keytruda's Subcutaneous Patent Infringement | HALO Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Halozyme Therapeutics Sues Merck Over Alleged Patent Infringement - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation | HALO Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

Halozyme Challenges Merck in Patent Battle Over Breakthrough Subcutaneous Keytruda Technology - Stock Titan

Apr 24, 2025
pulisher
Apr 22, 2025

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga

Apr 22, 2025
pulisher
Apr 20, 2025

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet - simplywall.st

Apr 20, 2025
pulisher
Apr 16, 2025

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity - Yahoo Finance

Apr 16, 2025
pulisher
Apr 11, 2025

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market - MSN

Apr 11, 2025
pulisher
Apr 11, 2025

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Pre - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Peering Into Halozyme Therapeutics's Recent Short Interest - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Argenx stock rises on FDA nod for Vyvgart Hytrulo (ARGX) - Seeking Alpha

Apr 11, 2025
pulisher
Apr 11, 2025

Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx - marketscreener.com

Apr 11, 2025
pulisher
Apr 10, 2025

Halozyme :FDA Oks Argenx' VYVGART Hytrulo Prefilled Syringe For Generalized Myasthenia Gravis & CIDP - Nasdaq

Apr 10, 2025
pulisher
Apr 10, 2025

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - Citizen Tribune

Apr 10, 2025
pulisher
Apr 10, 2025

J&J, Halozyme win EU nod for injectable Rybrevant in lung cancer - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewswire Inc.

Apr 10, 2025
pulisher
Apr 09, 2025

Halozyme Therapeutics (HALO) Gains EU Approval for Injectable Co - GuruFocus

Apr 09, 2025
pulisher
Apr 09, 2025

J&J, Halozyme get EU nod for Darzalex SC to treat multiple myeloma - Seeking Alpha

Apr 09, 2025
pulisher
Apr 09, 2025

European Commission Approved Subcutaneous Darzalex (Daratumumab) Based Quadruplet Regimen - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Halozyme Reports EC Approval For Indication Extension Of DARZALEX Co-formulated With ENHANZE - Nasdaq

Apr 09, 2025
pulisher
Apr 09, 2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - Quantisnow

Apr 09, 2025
pulisher
Apr 08, 2025

Halozyme Therapeutics : Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing 's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Bre - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Halozyme Therapeutics : To Receive $10 Million Milestone Payment From Janssen - MarketScreener

Apr 08, 2025
pulisher
Apr 07, 2025

Halozyme (HALO) Secures European Approval for J&J Antitumor Inje - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

EC approves new lung cancer treatment using Halozyme technology By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - The Malaysian Reserve

Apr 07, 2025
pulisher
Apr 07, 2025

Halozyme Says EC Approved Subcutaneous Rybrevant For Advanced EGFR-Mutated NSCLC - Nasdaq

Apr 07, 2025
pulisher
Apr 07, 2025

EC approves new lung cancer treatment using Halozyme technology - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

European Commission Approves Subcutaneous Rybrevant® (Amivantamab) - MarketScreener

Apr 07, 2025
pulisher
Apr 03, 2025

KLP Kapitalforvaltning AS Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Apr 03, 2025
pulisher
Apr 01, 2025

Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

4,812 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by EntryPoint Capital LLC - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Mar 31, 2025
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
大文字化:     |  ボリューム (24 時間):